MESO
Mesoblast LtdNASDAQ
Healthcare • Biotechnology
Updated 1 day ago
Coverage limited
$13.90-2.63%
Close Oct 13, 2026
- Market cap
- —
- 1 month
- -7.5%
- 3 months
- -23.8%
- 1 year
- -24.2%
- 52-week range
- $13.19$20.96
- Dividend
- No dividends on record
- Short interest
- 3.8% of float3.3M shares · settled Sep 30, 2026 · -0.2% since Sep 15, 2026 · FINRA
End-of-day close from stored market data, not a live quote.
Portfolio context
Sign in to see your position size
We’ll show you if MESO is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
Smart money context
Holder IQ: MEDIUM
12 top institutions tracked
as of 2026-Q2 (filed 2026-09-04)
Insider context
Sentiment: unknown
No recent insider trades detected.
Red flags: 3
Largest 13-F holders · Q2 2026
72 filers reported a long position in MESO for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| MORGAN STANLEY | $9.7M | 718.6K | +39.7% |
| BlackRock, Inc. | $9M | 664.3K | +5.3% |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $6.2M | 457.7K | +18.4% |
| GOLDMAN SACHS GROUP INC | $5.4M | 395.6K | -0.4% |
| BNP Paribas Asset Management Holding S.A. | $3.5M | 259.7K | New |
| UBS Group AG | $2.7M | 200.1K | +50.9% |
| Arax Advisory Partners | $2.3M | 168K | +587.9% |
| BANK OF AMERICA CORP /DE/ | $1.4M | 100K | 0% |
| Penbrook Management LLC | $1.2M | 87.1K | Unchanged |
| Fi3 FINANCIAL ADVISORS, LLC | $1M | 7.9K | -81.2% |
Get the Full Analysis for MESO
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.